These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18583342)

  • 1. Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis.
    Gébus C; Faudry E; Bohn YS; Elsen S; Attree I
    J Biol Chem; 2008 Aug; 283(35):23940-9. PubMed ID: 18583342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa.
    Sato H; Hunt ML; Weiner JJ; Hansen AT; Frank DW
    PLoS One; 2011 Mar; 6(3):e18356. PubMed ID: 21479247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
    Warrener P; Varkey R; Bonnell JC; DiGiandomenico A; Camara M; Cook K; Peng L; Zha J; Chowdury P; Sellman B; Stover CK
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4384-91. PubMed ID: 24841258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactions.
    Nanao M; Ricard-Blum S; Di Guilmi AM; Lemaire D; Lascoux D; Chabert J; Attree I; Dessen A
    BMC Microbiol; 2003 Oct; 3():21. PubMed ID: 14565848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of type III effector translocation by Yersinia pseudotuberculosis expressing native LcrV or PcrV from Pseudomonas aeruginosa.
    Bröms JE; Sundin C; Francis MS; Forsberg A
    J Infect Dis; 2003 Jul; 188(2):239-49. PubMed ID: 12854079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against
    Wan C; Zhang J; Zhao L; Cheng X; Gao C; Wang Y; Xu W; Zou Q; Gu J
    Front Immunol; 2019; 10():781. PubMed ID: 31068928
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LcrG Tip Chaperone Protein of the Yersinia pestis Type III Secretion System Is Partially Folded.
    Chaudhury S; de Azevedo Souza C; Plano GV; De Guzman RN
    J Mol Biol; 2015 Sep; 427(19):3096-109. PubMed ID: 26259880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes.
    Goure J; Pastor A; Faudry E; Chabert J; Dessen A; Attree I
    Infect Immun; 2004 Aug; 72(8):4741-50. PubMed ID: 15271936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between Yersinia pestis V-antigen (LcrV) and human Toll-like receptor 2 (TLR2) in a modelled protein complex and potential mechanistic insights.
    Wei T; Gong J; Qu G; Wang M; Xu H
    BMC Immunol; 2019 Dec; 20(1):48. PubMed ID: 31842739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutathionylation of
    Mitchell A; Tam C; Elli D; Charlton T; Osei-Owusu P; Fazlollahi F; Faull KF; Schneewind O
    mBio; 2017 May; 8(3):. PubMed ID: 28512097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV.
    Ivanov MI; Hill J; Bliska JB
    Clin Vaccine Immunol; 2014 May; 21(5):667-73. PubMed ID: 24599533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.
    Noel BL; Lilo S; Capurso D; Hill J; Bliska JB
    Clin Vaccine Immunol; 2009 Oct; 16(10):1457-66. PubMed ID: 19710295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by
    Das S; Howlader DR; Zheng Q; Ratnakaram SSK; Whittier SK; Lu T; Keith JD; Picking WD; Birket SE; Picking WL
    Front Immunol; 2020; 11():583008. PubMed ID: 33281815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the Yersinia pestis tip protein LcrV refined to 1.65 Å resolution.
    Chaudhury S; Battaile KP; Lovell S; Plano GV; De Guzman RN
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2013 May; 69(Pt 5):477-81. PubMed ID: 23695558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PcrG protects the two long helical oligomerization domains of PcrV, by an interaction mediated by the intramolecular coiled-coil region of PcrG.
    Basu A; Das U; Dey S; Datta S
    BMC Struct Biol; 2014 Jan; 14():5. PubMed ID: 24460624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor.
    Abramov VM; Khlebnikov VS; Vasiliev AM; Kosarev IV; Vasilenko RN; Kulikova NL; Khodyakova AV; Evstigneev VI; Uversky VN; Motin VL; Smirnov GB; Brubaker RR
    J Proteome Res; 2007 Jun; 6(6):2222-31. PubMed ID: 17441749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.